Inferra AIResearch Tools

Inferra AI / Company / RVMD

Revolution Medicines

RVMD · Health Care

Last earnings Aug 5, 2026

AI analysis

Q2 2025 · reported Aug 6, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

No guidance located in the held release

Outlook statement

“Financial Guidance Revolution Medicines is updating its full year 2026 GAAP operating expense guidance to a range of $2.1 to $2.2 billion, which includes estimated non-cash stock-based compensation expense of between $270 and $290 million.”

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Grow global commercialization and operational capabilities and advance launch readiness The company recently announced a partnership with Royalty Pharma, which provides $2 billion in committed capital to Revolution Medicines upon achievement of agreed-upon milestones through a flexible mix of synthetic royalty and debt instruments.

On an ongoing basis, management evaluates its estimates, including clinical accruals, useful lives of property and equipment and intangible assets, impairment of goodwill and intangibles, impairment of in-process research and development and developed technologies, the incremental borrowing rate for determining operating lease assets and liabilities, warrant liabilities, stock-based compensation, the liability related to the sale of future royalties including the estimation of future payments and the related non-cash interest expense.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress • Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

Grow global commercialization and operational capabilities and advance launch readiness The company recently announced a partnership with Royalty Pharma, which provides $2 billion in committed capital to Revolution Medicines upon achievement of agreed-upon milestones through a flexible mix of synthetic royalty and debt instruments.

SEC original ↗Revolution Medicines — Earnings release (8-K exhibit)EX-99Aug 6, 2025

On an ongoing basis, management evaluates its estimates, including clinical accruals, useful lives of property and equipment and intangible assets, impairment of goodwill and intangibles, impairment of in-process research and development and developed technologies, the incremental borrowing rate for determining operating lease assets and liabilities, warrant liabilities, stock-based compensation, the liability related to the sale of future royalties including the estimation of future payments and the related non-cash interest expense.

SEC original ↗Revolution Medicines — 10-Q Quarterly report10-QAug 5, 2026

The Company s investment policy limits investments to money market funds, certain types of debt securities issued by the U.

SEC original ↗Revolution Medicines — 10-Q Quarterly report10-QAug 5, 2026

government and its agencies, certificates of deposit, corporate debt and commercial paper, and places restrictions on the credit ratings, maturities and concentration by type and issuer.

SEC original ↗Revolution Medicines — 10-Q Quarterly report10-QAug 5, 2026

Recently adopted accounting pronouncements In November 2024, the FASB issued ASU 2024-04, Debt (Topic 470), Debt with Conversion and Other Options (Subtopic 470-20), Induced Conversions of Convertible Debt Instruments.

SEC original ↗Revolution Medicines — 10-Q Quarterly report10-QAug 5, 2026

ASU 2024-04 clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion.

SEC original ↗Revolution Medicines — 10-Q Quarterly report10-QAug 5, 2026

Strategy & priorities

The company continues to make meaningful progress on its near-term strategic priorities: Execute pivotal trials with daraxonrasib monotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) RASolute 302, a global Phase 3 trial of daraxonrasib in patients with previously treated PDAC, continues to enroll well.

SEC original ↗Revolution Medicines — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Generate sufficient data to inform development priorities for the mutant-selective inhibitors elironrasib and zoldonrasib and prepare to initiate one or more pivotal trials either as monotherapy or in a drug combination The company continues to study its mutant-selective inhibitors elironrasib and zoldonrasib as monotherapy and in drug combinations.

SEC original ↗Revolution Medicines — Earnings release (8-K exhibit)EX-99Aug 6, 2025

This flexible funding agreement provides the company with strategic agility and ability to secure the 3 resources needed to advance its ambitious global clinical development and commercialization plans.

SEC original ↗Revolution Medicines — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).

SEC original ↗Revolution Medicines — Earnings release (8-K exhibit)EX-99Aug 6, 2025

(the Company) is a late-stage clinical oncology company focused on developing novel targeted therapies for patients with RAS-addicted cancers.

SEC original ↗Revolution Medicines — 10-Q Quarterly report10-QAug 5, 2026

Risks & headwinds

Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements.

SEC original ↗Revolution Medicines — Earnings release (8-K exhibit)EX-99Aug 6, 2025

For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 6, 2025, and its future periodic reports to be filed with the SEC.

SEC original ↗Revolution Medicines — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Legal Proceedings 31 Item 1A.

SEC original ↗Revolution Medicines — 10-Q Quarterly report10-QAug 5, 2026

These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

SEC original ↗Revolution Medicines — 10-Q Quarterly report10-QAug 5, 2026

These forward-looking statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control.

SEC original ↗Revolution Medicines — 10-Q Quarterly report10-QAug 5, 2026

These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the section titled Risk Factors and elsewhere in this Quarterly Report on Form 10-Q.

SEC original ↗Revolution Medicines — 10-Q Quarterly report10-QAug 5, 2026

Documents

Earnings deck slides

0 decks with slide view

Revolution Medicines — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Revolution Medicines — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

60 documents

Earnings releases

15 documents

Presentations

2 documents

Transcripts

0 documents

No transcripts for Revolution Medicines are held in this edition of the library.

Mentioned by

1 company

Other tracked companies whose held documents mention Revolution Medicines by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.